Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Encorafenib→

Encorafenib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1269440-17-6
Molecular formula
C22H27ClFN7O4S
Molecular weight
540 g/mol
Drug class
BRAF kinase inhibitortargeted antineoplastic small molecule
Mechanism of action
Selectively inhibits BRAF V600-mutant kinase activity and downstream MAPK signalling. It is used in combination regimens with MEK or EGFR inhibition to limit pathway reactivation and improve antitumour activity.
Indications / reported uses
  • In combination with binimetinib for adults with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
  • In combination with cetuximab for adults with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy
  • Additional tumour-specific combinations and indications depend on the current product label and jurisdiction

Sources: US DailyMed — BRAFTOVI (encorafenib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Encorafenib Environmental Risk Assessment (ERA) (the Encorafenib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.